2023

  1. ICD-10-CM Codes
    2. ›
  2. C00-D49
    3. ›
  3. C7A-C7A
    4. ›
  4. C7A-
    5. ›
  5. 2023 ICD-10-CM Diagnosis Code C7A.1

2023 ICD-10-CM Diagnosis Code C7A.1

Malignant poorly differentiated neuroendocrine tumors

    2016 2017 2018 2019 2020 2021 2022 2023 Billable/Specific Code
  • C7A.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2023 edition of ICD-10-CM C7A.1 became effective on October 1, 2022.
  • This is the American ICD-10-CM version of C7A.1 - other international versions of ICD-10 C7A.1 may differ.
Applicable To
  • Malignant poorly differentiated neuroendocrine tumor NOS
  • Malignant poorly differentiated neuroendocrine carcinoma, any site
  • High grade neuroendocrine carcinoma, any site
The following code(s) above C7A.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C7A.1:
  • C00-D49
    2023 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C7A
    ICD-10-CM Diagnosis Code C7A

    Malignant neuroendocrine tumors

      2016 2017 2018 2019 2020 2021 2022 2023 Non-Billable/Non-Specific Code
    Code Also
    • any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)
    Type 2 Excludes
    • malignant pancreatic islet cell tumors (C25.4)
    • Merkel cell carcinoma (C4A.-)
    Use Additional
    • code to identify any associated endocrine syndrome, such as:
    • carcinoid syndrome (E34.0)
    Malignant neuroendocrine tumors
Approximate Synonyms
  • Malignant carcinoid tumor, poorly differentiated
  • Malignant neuroendocrine carcinoma, poorly differentiated
  • Malignant poorly different neuroendocrine cancer
  • Malignant poorly differentiated carcinoid tumor
  • Malignant poorly differentiated neuroendocrine tumor
  • Primary malignant neuroendocrine tumor, poorly differentiated
ICD-10-CM C7A.1 is grouped within Diagnostic Related Group(s) (MS-DRG v40.0):
  • 826 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with mcc
  • 827 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures with cc
  • 828 Myeloproliferative disorders or poorly differentiated neoplasms with major o.r. Procedures without cc/mcc
  • 829 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures with cc/mcc
  • 830 Myeloproliferative disorders or poorly differentiated neoplasms with other procedures without cc/mcc
  • 843 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with mcc
  • 844 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses with cc
  • 845 Other myeloproliferative disorders or poorly differentiated neoplastic diagnoses without cc/mcc

Convert C7A.1 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change

Diagnosis Index entries containing back-references to C7A.1:

ICD-10-CM Codes Adjacent To C7A.1
C7A.029 Malignant carcinoid tumor of the large intestine, unspecified portion
C7A.09 Malignant carcinoid tumors of other sites
C7A.090 Malignant carcinoid tumor of the bronchus and lung
C7A.091 Malignant carcinoid tumor of the thymus
C7A.092 Malignant carcinoid tumor of the stomach
C7A.093 Malignant carcinoid tumor of the kidney
C7A.094 Malignant carcinoid tumor of the foregut, unspecified
C7A.095 Malignant carcinoid tumor of the midgut, unspecified
C7A.096 Malignant carcinoid tumor of the hindgut, unspecified
C7A.098 Malignant carcinoid tumors of other sites
C7A.1 Malignant poorly differentiated neuroendocrine tumors
C7A.8 Other malignant neuroendocrine tumors
C7B Secondary neuroendocrine tumors
C7B.0 Secondary carcinoid tumors
C7B.00 …… unspecified site
C7B.01 …… of distant lymph nodes
C7B.02 …… of liver
C7B.03 …… of bone
C7B.04 …… of peritoneum
C7B.09 …… of other sites
C7B.1 Secondary Merkel cell carcinoma

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Advertise with Us | License ICD10 Data

Copyright © | ICD10data.com